Cancer risk in adherent users of polyurethane foam-containing CPAP devices for sleep apnoea. Issue 1 (14th July 2022)

• Record Type: Journal Article
• Authors: Justeau, Grégoire; Gervès-Pinquié, Chloé; Jouvenot, Marie; Pigeanne, Thierry; Launois, Sandrine; Leclair-Visonneau, Laurene; Masson, Philippe; Bizieux-Thaminy, Acya; Bailly, Sébastien; Meslier, Nicole; Sabil, Abdelkebir; Racineux, Jean-Louis; Trzepizur, Wojciech; Gagnadoux, Frédéric
• Is Part Of: European respiratory journal. Volume 60:Issue 1(2022)
• Publication Date: 2022-07-14
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00551-2022
• Languages: English
• ISSNs: 0903-1936

Abstract

On 14 June, 2021 Philipps Respironics (PR) emitted a voluntary recall notification for several sleep and respiratory care products, including continuous positive airway pressure (CPAP) devices used for obstructive sleep apnoea (OSA) therapy and ventilators. The polyester-based polyurethane (PE-PUR) sound abatement foam may break down into particles, which may enter the device's air tube and be inhaled or swallowed by the user. The volatile gas products (diethylene glycol, toluene di-isocyanate isomers, toluene diamine isomers) released during the degradation process have been suspected to present potential toxic and carcinogenic effects [1]. Whether prolonged exposure to these volatile compounds is associated with an increased risk of cancer in patients using PR devices for OSA is a crucial issue. Using clinical data from a retrospective longitudinal multicentre cohort linked with health administrative data, Kendzerska et al . [2] reported no increased all-cancer risk in 1220 patients treated for OSA with a PR device over a median follow-up time of 7.5 years. However, the lack of therapy adherence data did not make it possible to evaluate cancer risk in CPAP-adherent patients. Using propensity score matching within a nationwide study of patients with OSA, Palm et al . [3] reported an increased all-cancer and lung cancer incidence in counties prescribing ≥80% of CPAP devices containing polyurethane foam (PUF-CPAP) compared to patients from counties prescribing <10% of PUF-CPAP. However, the association disappeared in the sensitivity analysis excluding a Swedish county with known higher smoking rates. Sustained and adherent CPAP therapy of obstructive sleep apnoea using Philips Respironics devices containing polyester-based polyurethane foam, was not associated with an increased risk of cancer after a median follow-up time of 7.2 years https://bit.ly/3vBpUQE